The WACC of Imexpharm Corp (IMP.VN) is 7.3%.
| Range | Selected | |
| Cost of equity | 6.50% - 8.20% | 7.35% |
| Tax rate | 20.70% - 21.20% | 20.95% |
| Cost of debt | 4.00% - 8.70% | 6.35% |
| WACC | 6.4% - 8.2% | 7.3% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.39 | 0.43 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.50% | 8.20% |
| Tax rate | 20.70% | 21.20% |
| Debt/Equity ratio | 0.03 | 0.03 |
| Cost of debt | 4.00% | 8.70% |
| After-tax WACC | 6.4% | 8.2% |
| Selected WACC | 7.3% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for IMP.VN:
cost_of_equity (7.35%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.39) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.